This Month
The Netflix model used for going to the doctor
The Challenger winner of the Business to Consumer category, Updoc, has delivered compound annual growth of 200 per cent.
- Simon Evans
October
CSL pulls studies, trials on three therapies in late-stage setback
The biotech giant has not ruled out expanding its pipeline of treatments through acquisitions after a number of projects were put on hold.
- Michael Smith
Navis Capital prepares $1b-plus exit at Device Technologies
Latham is expected to use a successful exit of Device - which would also mark Navis Capital’s largest deal ever in Australia – to underpin the billion-dollar raise for his ninth fund in 2025.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Weight loss wars: a century on, the battle heats up
America’s Eli Lilly is locked in a fight with Denmark’s Novo Nordisk to control the weight loss market. One product could hold the key.
- Oliver Barnes
September
I-MED bidders wrap their heads around data breach
The Permira-owned radiology giant has been the subject of media reports alleging data breaches and misuse of patient data.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Exclusive
- Commercial real estate
BlackRock seeds $1.5b laboratory real estate fund
BlackRock is partnering with local private equity firm Wentworth Capital on a “pure play” laboratory fund that has already secured a number of seed assets
- Larry Schlesinger
Pro Medicus’ billionaire boss says simplicity secret of success
Pro Medicus’ stranglehold on cloud-imaging healthcare tech means its growth trajectory has a long way to go.
- Michael Smith
Bugger off, Brookfield: Insurers hit back at private hospital chain
The increasingly bitter feud between insurers and private health operators is getting personal.
- Tom McIlroy
Echo IQ placement ‘oversubscribed’; Ord Minnett on ticket
Bids were due at market close on Thursday, and it is understood demand exceeded $10 million.
- Sarah Thompson, Kanika Sood and Emma Rapaport
I took ecstasy at 50 and it changed my life
I got divorced, my father died, I cut ties with my mother, turned fifty, bought my first home of my own and did MDMA for the first time. This is an extract of the book that resulted.
- Rebecca Huntley
August
- Industry Engagement
- Higher Education Awards
La Trobe’s pioneering model to transform healthcare
The winner of the industry engagement award used COVID and a pinch of serendipity to create a world-leading virtual medical emergency model in Melbourne.
- Sylvia Ramsey
How medical research is failing women
For years, the process for developing and testing new drugs has focused disproportionately on male bodies — to the detriment of female patients.
- Sarah Neville
Four ways to sidestep knee surgery
Those suffering with osteoarthritis of the knee need to take more control of their condition, rather than sitting back and waiting for surgery.
- Jill Margo
Psychedelics as a serious investment? These billionaires think so
Australia is among the first countries to use the drugs for treating anxiety, depression and PTSD. A decision in the United States could be pivotal.
- Michael Smith
- Exclusive
- Weight loss
Ozempic maker wants taxpayer subsidy for new Wegovy drug
Danish pharmaceutical giant Novo Nordisk pulled in more than $600 million from Australia last year but reported just $17 million in profit here.
- Nick Bonyhady
June
Vapes would be sold like cigarettes under Coalition policy
Vapes would be subject to an excise tax that could raise billions of dollars annually, under a proposal unveiled by shadow health spokeswoman Anne Ruston.
- Ronald Mizen
The Ozempic effect: How weight loss wonder drug gobbled up an economy
Pharmaceutical giant Novo Nordisk has grown so large in its native Denmark that it’s hard to find staff. Meanwhile, its philanthropic foundation is running out of local causes to support.
- Sanne Wass and Naomi Kresge
May
The disease detectives trying to keep the world safe from bird flu
Frontline work in low-income countries is increasingly vital to a global system to detect viruses that jump between animals and humans, the way COVID-19 did.
- Stephanie Nolen
Behind Ian Malouf’s $50m bet on umbilical cords
The Dial-A-Dump founder has shrugged off doubts about stem cell therapy and is investing heavily to get the treatments more widely approved.
- Michael Bailey
Aussies aren’t all Bondi Beach fit, Ozempic’s new local exec has just realised
Novo Nordisk Oceania managing director Cem Ozenc mourns the fact Australia’s obesity challenge is lost amid the celebrity hype surrounding the medication.
- Sally Patten